New statewide coalition calls on Albany to pass S.9289/A.10401 and close the transportation gap leaving students experiencing homelessness, foster care, and IEP placements without...
The fast-growing startup partners with schools and leading kids' activity brands to help families book trusted camps, classes, and after-school programs. DALLAS and...
MARTINSVILLE, Ind., June 2, 2026 /PRNewswire/ -- In conjunction with the bipartisan Congressional Camp Caucus, the American Camp Association (ACA) will convene congressional leaders, camp...
ATLANTA, June 02, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced that it completed its acquisition of Family First Holding, LLC ("Family First Homecare").
AddiVance is formulated to support focus, attention, mood balance, and everyday cognitive performance as part of a healthy lifestyleWEST CHESTER, Ohio, June 1, 2026...
Jon Keyser Appointed Interim Chief Executive OfficerMESA, Ariz., June 1, 2026 /PRNewswire/ -- Verra Mobility Corporation (NASDAQ: VRRM), a leading provider of smart mobility...
SAN DIEGO, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of KinderCare Learning Companies, Inc. (NYSE: KLC) common stock in or traceable to KinderCare’s October 2024 initial public offering (“IPO”), have until October 13, 2025 to seek appointment as lead plaintiff of the KinderCare class action lawsuit. Captioned Gollapalli v. KinderCare Learning Companies, Inc., No. 25-cv-01424 (D. Or.), the KinderCare class action lawsuit charges KinderCare as well as certain of KinderCare’s top executives and directors, KinderCare’s controlling shareholder, and the underwriters of the IPO with violations of the Securities Act of 1933.
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity.
SAN FRANCISCO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Gollapalli v. KinderCare Learning Companies, Inc., et al., No. 3:25-cv-01424 (D. Or.) has been filed and seeks to represent investors who purchased KinderCare (NYSE: KLC) common stock in or traceable to the company’s October 2024 IPO.